Q1 Earnings Forecast for SPRY Issued By Roth Capital

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Stock analysts at Roth Capital issued their Q1 2027 EPS estimates for ARS Pharmaceuticals in a report released on Tuesday, November 4th. Roth Capital analyst K. Bauser forecasts that the company will post earnings per share of ($0.29) for the quarter. Roth Capital has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals’ Q2 2027 earnings at $0.02 EPS and Q3 2027 earnings at $0.41 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.The business had revenue of $15.72 million during the quarter, compared to the consensus estimate of $12.92 million.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 22nd. Finally, Raymond James Financial set a $32.00 price objective on shares of ARS Pharmaceuticals in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $31.80.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock opened at $8.71 on Wednesday. The stock’s fifty day moving average is $10.21 and its 200 day moving average is $13.70. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.98 and a current ratio of 6.17. ARS Pharmaceuticals has a one year low of $8.32 and a one year high of $18.90. The stock has a market cap of $860.77 million, a P/E ratio of -17.78 and a beta of 0.83.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently made changes to their positions in the company. CWM LLC increased its stake in ARS Pharmaceuticals by 243.7% in the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after acquiring an additional 1,806 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in ARS Pharmaceuticals in the first quarter worth $37,000. PNC Financial Services Group Inc. increased its position in ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock worth $49,000 after purchasing an additional 3,905 shares during the last quarter. Osaic Holdings Inc. increased its position in ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after purchasing an additional 1,803 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock worth $98,000 after purchasing an additional 777 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Richard E. Lowenthal sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $14.49, for a total transaction of $724,500.00. Following the sale, the chief executive officer owned 1,196,494 shares in the company, valued at $17,337,198.06. This trade represents a 4.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kathleen D. Scott sold 12,500 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $187,500.00. Following the sale, the chief financial officer owned 10,042 shares in the company, valued at approximately $150,630. The trade was a 55.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 112,500 shares of company stock worth $1,615,759 over the last quarter. Insiders own 33.50% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.